Titre du document / Document title

Varenicline : An oral partial nicotine agonist for smoking cessation

Auteur(s) / Author(s)

FERET Brett ; ORR Kelly ;

Résumé / Abstract

Varenicline (Chantix, Pfizer) is a partial nicotine receptor agonist with a high affinity for the alpha-4 beta-2 nicotinic acetylcholine receptors, modulating dopamine levels associated with nicotine addiction and aiding in smoking cessation. Clinical studies have demonstrated favorable cessation rates compared with placebo and sustained-release bupropion, with an encouraging safety profile. The most common adverse effect seen in clinical trials was mild-to-moderate nausea. In November 2005, a New Drug Application (NDA) was submitted for varenicline, and the drug was subsequently granted a 6-month priority review. On May 10, 2006, varenicline became the first oral medication approved for smoking cessation since bupropion, representing an agent with a novel mechanism of action for smoking cessation.

Revue / Journal Title

Formulary   ISSN 1082-801X 

Source / Source

2006, vol. 41, n^o6, [Note(s): 265-272 [5 p.]]

Langue / Language

Anglais

Editeur / Publisher

Advanstar Communications, Duluth, MN, ETATS-UNIS  (1995) (Revue)

Localisation / Location

INIST-CNRS, Cote INIST : 14203, 35400013888061.0010